Drug Trial Radar · NCT07174414
Cilostazol for Prevention of Recurrent Stroke Trial
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,000
Planned (sponsor's estimate)
Start
Oct 15, 2026
Primary completion
Jul 2031
Study completion Jul 2031
Sponsor
- Lead sponsor
- Stanford UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Neurological Disorders and Stroke (NINDS); Yale University; University of Cincinnati; Medical University of South Carolina
- First posted
- Sep 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to learn if adding a medicine called cilostazol to usual treatment can help prevent another stroke, a heart attack, or death in patients who had a stroke caused by a blocked blood vessel, or a "mini-stroke" (also called a TIA), in the past 6 months. To determine if cilostazol is safe and effective at lowering the chance of strokes, heart attacks and deaths, the study will compare cilostazol to a placebo, a pill that looks the same as cilostazol but has no medicine in it. Participants will: * Be assigned by chance to take either cilostazol or a placebo, along with their usual medicine. * Not know which one they are taking, and neither will the study team, which keeps the results fair. * Be followed for up to 5 years to see if they have a stroke, heart attack, or major bleeding. See the Clarity study website for more information: https://www.claritystrokestudy.org/
Conditions
- Stroke Recurrence
- Myocardial Infarction
- Vascular Death
- Ischemic Stroke
- TIA (Transient Ischemic Attack)
- Stroke (CVA) or Transient Ischemic Attack
- Recurrent Stroke
Interventions
Cilostazol 100 mg TabletsDrug
The standard dosing regimen is an initial 2-week period during which participants take one tablet of cilostazol (100 mg) orally once daily followed by a maintenance phase in which they take one tablet twice daily. For participants who are on certain interacting drugs or who experience adverse reactions on the standard dosing regimen, the dose is reduced to half a tablet twice daily.
PlaceboDrug
The standard dosing regimen is an initial 2-week period during which participants take one placebo tablet, which matches cilostazol 100 mg tablets, orally once daily followed by a maintenance phase in which they take one tablet twice daily. For participants who are on certain interacting drugs or who experience adverse reactions on the standard dosing regimen, the dose is reduced to half a tablet twice daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to first occurrence of any component of the composite of ischemic stroke, acute myocardial infarction, or ischemic vascular death (MACE).Time frame: Up to 5 years after randomization
Locations
54 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama Hospital - Birmingham
Birmingham, Alabama · Recruiting
Chandler Regional Medical Center
Chandler, Arizona · Recruiting
Kaiser Permanente Fontana Medical Center
Fontana, California · Recruiting
UCSD Health La Jolla
La Jolla, California · Recruiting
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California · Recruiting
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
Casa Colina Hospital
Pomona, California · Recruiting
Kaiser Permanente San Diego Medical Center
San Diego, California · Recruiting
Stanford University
Stanford, California · Recruiting
Intermountain Health - St. Mary's Medical Center
Grand Junction, Colorado · Recruiting
Yale New Haven Hospital
New Haven, Connecticut · Recruiting
UF Health Jacksonville
Jacksonville, Florida · Recruiting
Emory University Hospital
Atlanta, Georgia · Recruiting
Grady Memorial Hospital
Atlanta, Georgia · Recruiting
Memorial Hospital of Carbondale
Carbondale, Illinois · Not yet recruiting
University of Iowa Medical Center
Iowa City, Iowa · Recruiting
University of Kansas Hospital
Kansas City, Kansas · Recruiting
University of Maryland Medical Center
Baltimore, Maryland · Not yet recruiting
Boston Medical Center
Boston, Massachusetts · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
University of Michigan - University Hospital
Ann Arbor, Michigan · Recruiting
Mclaren Flint
Flint, Michigan · Recruiting
Abbott Northwestern Hospital
Minneapolis, Minnesota · Recruiting
M Health Fairview University of Minnesota Medical Center
Minneapolis, Minnesota · Recruiting
Regions Hospital
Saint Paul, Minnesota · Recruiting
Barnes-Jewish Hospital
St Louis, Missouri · Recruiting
SSM Health St. Louis University Hospital
St Louis, Missouri · Recruiting
Kings County Hospital Center
Brooklyn, New York · Recruiting
NYU Langone Hospital - Brooklyn
Brooklyn, New York · Recruiting
NYP Weill Cornell Medical Center
New York, New York · Not yet recruiting
Duke University Hospital
Durham, North Carolina · Not yet recruiting
New Hanover Regional Medical Center
Wilmington, North Carolina · Recruiting
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina · Recruiting
Cleveland Clinic Akron General
Akron, Ohio · Not yet recruiting
University of Cincinnati
Cincinnati, Ohio · Recruiting
OSU Wexner Medical Center
Columbus, Ohio · Recruiting
Oklahoma University Medical Center
Oklahoma City, Oklahoma · Recruiting
Providence St. Vincent Medical Center
Portland, Oregon · Not yet recruiting
Oregon Health & Science University Hospital
Portland, Oregon · Recruiting
UPMC Hamot
Erie, Pennsylvania · Not yet recruiting
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.